Back to Results
First PageMeta Content
Hepatorenal syndrome / Syndromes / Hypertension / Pulmonary hypertension / Nitric oxide / Heart failure / Health / Chemistry / Medicine


LUCASSIN® APPROVED IN AUSTRALIA Hampton, NJ and Melbourne – April 23, 2012 – Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announce
Add to Reading List

Document Date: 2012-05-29 13:53:20

Open Document

File Size: 73,63 KB

Share Result on Facebook

City

Madison / Melbourne / Hampton / /

Company

Ikaria Inc. / Ikaria Australia Pty Ltd / /

Continent

North America / /

Country

Puerto Rico / France / Japan / United States / Canada / Australia / Mexico / Spain / South Korea / Ireland / /

Event

FDA Phase / M&A / /

Facility

Port Allen / /

IndustryTerm

drug-device combination product / drug product / treatment of Hepatorenal Syndrome / treatment of hypoxic respiratory failure / manufacturing facilities / treatment for Hepatorenal Syndrome / /

MedicalCondition

bronchopulmonary dysplasia / advanced liver cirrhosis / pulmonary arterial hypertension / chronic obstructive pulmonary disease / pulmonary hypertension / subsequent congestive heart failure / kidney failure / renal failure / hypoxic respiratory failure / acute myocardial infarction / /

MedicalTreatment

innovative therapies / liver transplant / /

Organization

Therapeutic Goods Administration / FDA / /

Person

Daniel Tassé / Lorna Meldrum / /

Position

General Manager / Chairman and CEO / /

Product

INOMAX / LUCASSIN® (terlipressin) / LUCASSIN / France / /

ProvinceOrState

New Jersey / Wisconsin / /

Technology

drug-delivery system / /

URL

www.ikaria.com / /

SocialTag